Literature DB >> 12470041

Perioperative blood management practices in elective orthopaedic surgery.

E Michael Keating1, John B Meding.   

Abstract

Concern about the cost and safety of allogenic blood transfusion, including the risk of viral infection and immunosuppression, has led to refinements in and new approaches to blood conservation, including the development of transfusion practice standards and improvements in surgical practice. Preoperative autologous blood collection, the use of hemostatic agents, perioperative blood salvage, and the use of recombinant human erythropoietin (epoetin alfa) to stimulate erythropoiesis have contributed to decreased use of allogenic blood services. Development of appropriate blood management strategies to help reduce or eliminate exposure to allogenic blood requires a preoperative assessment of the likelihood of transfusion and of the risks as well as costs associated with conservation and replacement options. The informed selection of alternatives based on preoperative assessment of hematologic status, estimated blood loss, and sources for blood replacement may enhance blood management practices in major elective orthopaedic surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470041     DOI: 10.5435/00124635-200211000-00003

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  20 in total

Review 1.  Transfusion of post-operative shed blood: laboratory characteristics and clinical utility.

Authors:  M Muñoz; J J García-Vallejo; M D Ruiz; R Romero; E Olalla; C Sebastián
Journal:  Eur Spine J       Date:  2004-05-08       Impact factor: 3.134

2.  Recommendations for the transfusion management of patients in the peri-operative period. III. The post-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-04-20       Impact factor: 3.443

3.  Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-04       Impact factor: 3.443

4.  Does Tranexamic Acid Reduce Blood Loss and Transfusion Requirements Associated With the Periacetabular Osteotomy?

Authors:  Scott A Wingerter; Angela D Keith; Perry L Schoenecker; Geneva R Baca; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2015-05-20       Impact factor: 4.176

5.  Are we all guilty of under-estimating intra-operative blood loss during hip fracture surgery?

Authors:  Basil Budair; Usman Ahmed; James Hodson; Michael David; Mujeeb Ashraf; Tim McBride
Journal:  J Orthop       Date:  2016-10-28

6.  Cost benefit analysis of the use of tranexamic acid in primary lower limb arthroplasty: A retrospective cohort study.

Authors:  Niall P McGoldrick; Eabhann M O'Connor; Nikos Davarinos; Rose Galvin; John F Quinlan
Journal:  World J Orthop       Date:  2015-12-18

7.  Analysis of a large data set to identify predictors of blood transfusion in primary total hip and knee arthroplasty.

Authors:  ZeYu Huang; Cheng Huang; JinWei Xie; Jun Ma; GuoRui Cao; Qiang Huang; Bin Shen; Virginia Byers Kraus; FuXing Pei
Journal:  Transfusion       Date:  2018-08-25       Impact factor: 3.157

Review 8.  Preoperative erythropoietin in spine surgery.

Authors:  Maria J Colomina; Juan Bagó; Ferran Pellisé; Carmen Godet; Carlos Villanueva
Journal:  Eur Spine J       Date:  2004-06-09       Impact factor: 3.134

9.  [Analgaesia, anaesthesia, and rehabilitation for minimally invasive total knee arthroplasty].

Authors:  M Pietsch; S Hofmann
Journal:  Orthopade       Date:  2007-12       Impact factor: 1.087

10.  Pneumatic wound compression after hip fracture surgery did not reduce postoperative blood transfusion: A randomized controlled trial involving 292 fractures.

Authors:  Anna Apelqvist; Markus Waldén; Gert-Uno Larsson; Isam Atroshi
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.